Mammogen Featured in Forbes: Advancing the Future of Breast Cancer Detection

November 3, 2026

November 3, 2026 | In the News | Forbes


Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing.


The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue.


At the center of the story is genTRU-breast™, Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions.


The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation.


A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™.


As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care.


Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test


Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.

October 9, 2026
Rockford News First | October 9, 2026
June 30, 2025
Renowned global builder of boards and executive teams aligns with leading women's health innovator, signaling next phase of commercial growth
December 2, 2023
Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer
December 2, 2023
272 | "Changing Lives Through Early Disease Detection" with Marty Keiser from IVBH Studio
November 16, 2023
World's First Early Detection Blood Test to Unlock Stage I Diagnosis of Breast Cancer
By Eric Kristiansen • June 4, 2023
IVBH's novel RNA approach to early detection demonstrates strong sensitivity and specificity for early lung cancer detection, in a large, predominantly early-stage, independent validation cohort
By Marty Keiser • March 22, 2023
A decade in the making, AI is suddenly everything, everywhere, all at once. In this article I outline three major themes emerging in the current environment. 1. Industrialization. We have officially entered the industrialization era of AI. With the most complex technical foundation already having been laid, success is no longer about the quality of your code, but rather the quality of your prompts. Any person with the right idea, the right focus, and the right prompts, can now solve any problem, in any industry, regardless of their background, socioeconomic status or geography. The floodgates for innovation have officially been opened. 2. Business disruption. Big missions no longer require big teams, big infrastructure, or big budgets. In fact, in the age of abundance, these things are detractors from the mission. Regime change is underway and small, nimble, multi-disciplinary teams who leverage big data and generalized AI tools in a highly specialized way should not be underestimated or undervalued. Size is no longer an advantage, it’s an Achilles heel. 3. People disruption. AI has reached a point where it can now scale humans. The net effect of this is a devaluing of humans without AI, and a devaluing of AI without humans. The two can no longer be treated as mutually exclusive. Humans who fully embrace AI with intention and purpose will win, and they will win big. (The humans who do this most effectively within this decade will be the winners for the next century.)